Novartis agreed to pay $125 million to acquire a Sironax blood-brain barrier (BBB) crossing technology, securing a platform intended to move multiple modalities into the CNS. The deal hands Novartis global rights to the platform and is expected to support three candidates that Sironax says have “best-in-class” potential. The acquisition comes as Novartis navigates broader R&D pressure, including neuroscience pipeline setbacks. By adding a BBB delivery approach, Novartis is aiming to reduce one of the most persistent constraints in CNS drug development. For CNS-focused biotech and pharma, the transaction underscores that delivery platforms remain high-value assets when clinical data and target biology are present but exposure at the brain interface is the bottleneck.